that targets eukaryotic translation elongation factor 1α (eEF1A) and displays potent antiproliferative activities. Herein, a series of nannocystin A analogues were synthesized and their structure–activity relationship (SAR) were established based on the MTT assay and western blotting analysis. The SAR enabled us to identify a structurally simplified nannocystin A analogue LQ18, which exhibited potent
Nannocystin A是一种新型的21元大环内酰胺,其靶向真核翻译延伸因子1α(eEF1A)并显示出强大的抗增殖活性。在此,合成了一系列nannocystin A类似物,并基于M
TT分析和western印迹分析建立了它们的结构-活性关系(
SAR)。
SAR使我们能够鉴定结构简化的nannocystin A类似物LQ18,它对测试的
细胞系表现出有效的抗增殖活性,IC 50值范围为4.3至48 nM,并抑制了A549
细胞系中eEF1A1的表达。LQ18使细胞周期停滞在G2期,并通过以下途径诱导A549细胞凋亡caspase-3,caspase-9和bax蛋白表达上调呈剂量依赖性,而bcl-2表达明显降低。总体而言,这些数据表明,LQ18可能是开发用于癌症治疗的结构新颖的eEF1A1
抑制剂的有希望的先导。